From the editorial desk

Evidence Analysis

The NIA Interventions Testing Program: what the most rigorous longevity drug testing found

The ITP has tested dozens of interventions for lifespan extension in mice at three independent sites. Here is what it found — and what the results mean for translating to humans.

July 19, 2026  ·  12 min read

Evidence Analysis

Biological age vs. chronological age: how aging is measured and what the tests tell you

Epigenetic clocks, telomere length, proteomics, metabolomics — multiple methods claim to measure biological age. Here is what each measures, how they compare, and what they cannot tell you.

July 19, 2026  ·  13 min read

Evidence Analysis

Longevity medicine vs. the anti-aging industry: distinguishing science from noise

Both longevity medicine and the anti-aging supplement industry use the same vocabulary. Here is a structured framework for telling them apart — and why the distinction matters clinically.

July 19, 2026  ·  10 min read

Evidence Analysis

Metformin vs. rapamycin: comparing the longevity evidence head-to-head

Both metformin and rapamycin target aging biology through related but distinct pathways. Here is a direct comparison of mechanism, evidence strength, and clinical profile.

July 19, 2026  ·  13 min read

Evidence Analysis

SGLT2 inhibitors vs. GLP-1 agonists: which has stronger longevity evidence?

Both drug classes have strong cardiovascular outcome trial data. Both are prescribed in longevity medicine. Here is how the evidence for each compares across mechanism, outcomes, and patient profile.

July 19, 2026  ·  12 min read

Longevity Science

The mTOR pathway and aging: a clinical reference for longevity medicine

mTOR is the central nutrient-sensing hub that rapamycin inhibits. Understanding it is prerequisite to understanding half the longevity pharmacopeia. Here is what the pathway does and why it matters clinically.

July 19, 2026  ·  14 min read

Longevity Science

The AMPK pathway and aging: what metformin, exercise, and caloric restriction have in common

AMPK is the energy-sensing kinase activated by metformin, exercise, and caloric restriction. Here is what the pathway does, how interventions activate it, and what the longevity evidence shows.

July 19, 2026  ·  13 min read

Longevity Science

Autophagy and longevity medicine: the clinical relevance of cellular recycling

Autophagy — the cellular recycling system — declines with age and is activated by rapamycin, fasting, and exercise. Here is what the evidence shows for interventions that target it.

July 19, 2026  ·  12 min read

Longevity Science

Cellular senescence and senolytics: the biology and evidence for clearing aged cells

Senescent cells accumulate with age and drive inflammation through the SASP. Senolytics clear them. Here is what the biology is, what the human evidence shows, and what remains to be established.

July 19, 2026  ·  13 min read

Evidence Analysis

The best-evidenced longevity drugs in 2026, ranked by trial data

Every longevity compound currently tracked on Geroevidence, ranked by evidence strength rather than hype — from Phase III outcome trials down to early-stage signals.

June 24, 2026  ·  12 min read

Clinical Trials

Could semaglutide become an anti-aging drug? The SELECT trial and beyond

Semaglutide's weight-loss story is well known. The cardiovascular outcome data is the more significant — and less discussed — longevity story.

June 24, 2026  ·  11 min read

Evidence Analysis

Why most longevity supplements lack human trial data

A structural explanation of why most longevity supplements have animal data but not human outcome trials — and how to tell the difference when evaluating a claim.

June 24, 2026  ·  8 min read

Longevity Science

Epigenetic clocks explained: what biological age tests can and can't tell you

Direct-to-consumer biological age tests have become a popular longevity-adjacent product. Here is what the underlying science measures, and what it doesn't yet validate.

June 24, 2026  ·  9 min read

Longevity Science

Is longevity medicine legitimate? What the research community actually says

The field spans serious NIH-funded geroscience and unregulated supplement marketing, often using the same vocabulary. Distinguishing them requires looking at specific claims, not the field as a whole.

June 24, 2026  ·  9 min read

Evidence Analysis

NAD+ IV therapy vs. NMN and NR supplements: comparing the evidence

NAD+ IV drips have become a popular wellness-clinic offering. Here is how the evidence for IV NAD+ compares to oral NMN and NR precursors.

June 24, 2026  ·  10 min read